|1.||Johnson, Steven A: 3 articles (02/2008 - 08/2002)|
|2.||Le, Alexander M: 1 article (11/2014)|
|3.||Su, Chen: 1 article (11/2014)|
|4.||Lee, Michelle: 1 article (11/2014)|
|5.||Wang, Jing: 1 article (11/2014)|
|6.||Zou, Anthony: 1 article (11/2014)|
|7.||Olsen, Christina Kurre: 1 article (11/2009)|
|8.||Glenthøj, Birte Yding: 1 article (11/2009)|
|9.||Broberg, Brian Villumsen: 1 article (11/2009)|
|10.||Larsen, Dorrit Bjerg: 1 article (11/2009)|
|1.||Schizophrenia (Dementia Praecox)
10/01/2001 - "These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia."
11/01/2009 - "The current study evaluated the effect of ampakine CX516 in reversing deficits in executive functioning as represented in two animal models of schizophrenia and assessed by a rodent analog of the intradimensional-extradimensional (ID-ED) attentional set-shifting task. "
02/01/2008 - "A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia."
02/01/2008 - "CX516 is the first Ampakine to be studied for cognitive enhancement in schizophrenia. "
10/01/2002 - "Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series."
|2.||Fragile X Syndrome (Martin Bell Syndrome)
10/01/2006 - "A Phase II, 4-week randomized, double-blind, placebo-controlled clinical trial was conducted to evaluate the safety and efficacy of the Ampakine compound CX516 as a potential treatment for the underlying disorder in fragile X syndrome (FXS). "
10/01/2006 - "Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial."
|3.||Alzheimer Disease (Alzheimer's Disease)
01/01/2006 - "Randomised trial data are available for antihypertensive agents (calcium channel blockers, angiotensin-converting enzyme inhibitors), pravastatin, simvastatin, conjugated oestrogen, raloxifene, rofecoxib, CX516 (AMPA agonist) and cholinesterase inhibitors regarding efficacy for Alzheimer's disease prevention. "
|4.||Memory Disorders (Memory Loss)
|5.||Autistic Disorder (Autism)
|1.||alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)
|5.||Cholinesterase Inhibitors (Anticholinesterases)
|6.||Calcium Channel Blockers (Blockers, Calcium Channel)
|7.||Antihypertensive Agents (Antihypertensives)
|8.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)